The Role of Baseline Total Kidney Volume Growth Rate in Predicting Tolvaptan Efficacy for ADPKD Patients: A Feasibility Study.
Dev H, Hu Z, Blumenfeld JD, Sharbatdaran A, Kim Y, Zhu C, Shimonov D, Chevalier JM, Donahue S, Wu A, RoyChoudhury A, He X, Prince MR.
Dev H, et al.
J Clin Med. 2025 Feb 21;14(5):1449. doi: 10.3390/jcm14051449.
J Clin Med. 2025.
PMID: 40094908
Free PMC article.
Mean annual rate of eGFR decline was less in responders than in non-responders (-0.25 0.04, CI: [-0.27, -0.23] mL/min/1.73 m(2) per year vs. -0.40 0.06, CI: [-0.43, -0.37] mL/min/1.73 m(2) per year, p = 0.036). ...
Mean annual rate of eGFR decline was less in responders than in non-responders (-0.25 0.04, CI: [-0.27, -0.23] mL/min/1.73 m(2) per y …